Terry Kohler - Aug 24, 2023 Form 4/A - Amendment Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Aug 24, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
2/6/2025, 04:15 PM
Date Of Original Report
Aug 28, 2023
Previous filing
Mar 3, 2023
Next filing
Nov 16, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Award $0 +125K $0.00 125K Aug 24, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.
F2 The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.